SBWire (press release) The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal . Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have ... and more »
Epilepsy Research UK The publication, entitled 'PharmaPoint: Epilepsy – UK Drug Forecast and Market Analysis to 2022′, confirms that levetiracetam (brand name Keppra) and lamotrigine ( Lamictal ) still dominate the market. Levetiracetam is used to treat partial onset ... and more »
